Mazindol hydrochloride | 58535-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: Mazindol hydrochloride
• 英文别名: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol;hydrochloride
• CAS: 58535-70-9
• 化学式: C16H14Cl2N2O
• 分子量: 321.2
• InChiKey: NIUFFPYONFMTAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.03
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  35.8
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
  申请人：Tris Pharma, Inc.

  公开号：US11337919B2

  公开（公告）日：2022-05-24

  An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

  本发明提供了一种可口服的药物粉末组合物，该组合物可形成具有至少两个触发脉冲的胃保留型 RAFT。该组合物至少包含：(a) 至少一种速释脉冲释放形式的药物；(b) 至少一种延迟触发释放形式的药物；(c) 至少一种无毒气体发生剂和 (d) 一种 RAFT 系统，其中，口服后，该组合物提供一种自组装的胃保留 RAFT，其中夹带有 (a) 和 (b) 中的至少一种药物以及由无毒气体发生剂在原位产生的气体、从而提供一种具有双脉冲系统的浮动胃保留型RAFT，其中至少第二个脉冲是触发脉冲，并将至少一种药物保留在胃中至少约3小时，前提是该组合物不包括γ-羟丁酸及其盐类、水合物、同系物或溶解物或其复合物。
• PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM
  申请人：Tris Pharma, Inc.

  公开号：EP3740188A1

  公开（公告）日：2020-11-25
• MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE
  申请人：Tris Pharma, Inc.

  公开号：US20210015745A1

  公开（公告）日：2021-01-21

  An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.